The most common form of bladder cancer is urothelial carcinoma, and it arises in cells that compose tubes in the kidneys and ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

This is the first comprehensive immunohistochemical analysis of the expression of several class I HDAC proteins (1, 2 and 3) in urothelial ... of patients with bladder cancer.

The move affects the accelerated approval for Trodelvy in advanced urothelial cancer ... Trodelvy earned its bladder cancer nod in 2021 based on single-arm, phase 2 data showing the drug triggered ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

His team analyzed literature on miRNA, summarizing the close relationship between these small molecules and cancer. miRNA is a type of non-coding RNA that does not encode proteins, but can target ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer ... with metastatic urothelial cancer in 2021, while its ...

While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Recent analysis from the National Cancer Database (NCDB) reveals a significant uptick in immunotherapy (IO) use for advanced ...